Outlook Therapeutics (OTLK)
NASDAQ:OTLK
Want to see OTLK full AI Analyst Report?
OTLK Stock Chart & Stats
$0.31
-$0.17(-7.61%)
At close: 4:00 PM EST
$0.31
-$0.17(-7.61%)
Day’s Range― - ―
52-Week Range$0.16 - $3.39
Previous CloseN/A
Volume358.39K
Average Volume (3M)28.06M
Market Cap
$163.45M
Enterprise Value-$7.53T
Total Cash (Recent Filing)$7.75M
Total Debt (Recent Filing)$27.19M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Aug 13, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.36
Shares Outstanding148,587,110
10 Day Avg. Volume21,150,661
30 Day Avg. Volume28,064,058
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-1.15
Price to Sales (P/S)26.09
P/FCF Ratio-0.71
Enterprise Value/Market Cap-46.07K
Enterprise Value/Revenue-22.60M
Enterprise Value/Gross Profit6.26M
Enterprise Value/Ebitda121.29K
Forecast
1Y Price Target
$0.50Price Target Upside61.29% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$16.01M
Bulls Say, Bears Say
Bulls Say
Regulatory Progress: FDA Appeal & Class 1 ResubmissionThe successful FDA appeal and Class 1 resubmission create a materially accelerated regulatory pathway. A U.S. approval would establish the first ophthalmic bevacizumab label, delivering durable market access, stronger negotiating power with payers and distributors, and a structural competitive edge in retina therapeutics.
Clinical Efficacy And Safety EvidenceRobust Phase 3 efficacy and an absence of FDA-raised safety issues strengthen the product's clinical value proposition. Durable efficacy/safety data underpin physician adoption, reimbursement discussions, and long-term commercial uptake if approved, reducing execution risk versus candidates lacking clear outcomes.
Access To Public Capital Via Shelf And ATMAn effective shelf and a $100M ATM program supply structural financing optionality to fund late‑stage regulatory activities, commercialization setup, or partnerships. Long‑term access to equity markets, if managed prudently, supports strategic choices and reduces the risk of abrupt funding gaps during commercialization.
Bears Say
Persistently Negative Shareholder EquityDeep, persistent negative equity signals cumulative losses that have eroded the capital base, limiting financial flexibility for capex, marketing, or commercial scale‑up. This structural weakness raises creditor and counterparty risk and can impede partnership or supplier terms needed for multi‑year commercialization.
Consistent Operating Cash BurnOngoing negative operating and free cash flow indicate the business cannot self‑fund development or launch activities. Over multi‑month horizons this necessitates external capital, increases execution risk for commercialization, and makes long‑term planning contingent on successful fundraising or partnerships.
Repeated Dilutive Financings And Restrictive DebtFrequent registered/direct offerings, heavy warrant issuance, and refinancing with restrictive covenants create chronic dilution risk and conditional capital access. Restrictive note terms and 'substantial doubt' language structurally raise the probability of future equity issuance, complicating long‑term shareholder value and execution of commercial plans.
Outlook Therapeutics News
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $0.16 and its highest was $3.39 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market cap is $163.45M.
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is Aug 13, 2026 which is in 60 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on May 15, 2026. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.121 by -$0.039.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -0.11.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 148,587,110 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.121. Following the earnings report the stock price went up 0.439%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Currently, no hedge funds are holding shares in OTLK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Outlook Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$0.50 (61.29% Upside)
$0.50 (61.29% Upside)
Blogger Sentiment
Bullish
OTLK Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 151.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.4%
Last 30 Days ▲ 13.5%
Last 30 Days ▲ 13.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.69%
12-Months-Change
Fundamentals
Return on Equity
<0.01%
Trailing 12-Months
Asset Growth
14.77%
Trailing 12-Months
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
OTLK Stock 12 Month Forecast
Average Price Target
$0.50
▲(61.29% Upside)
Technical Analysis
Ownership Overview
15.29% Insiders
1.51% Mutual Funds
3.79% Other Institutional Investors
77.99% Public Companies and Individual Investors